Rezolute (RZLT) Leases (2019 - 2026)
Rezolute recorded quarterly Leases of $918000.0 in Q1 2026, down 13.72% quarter-over-quarter from $1.1 million in Q4 2025, and down 38.18% year-over-year from $1.5 million in Q1 2025.
Rezolute's Leases history runs 8 years deep, the most recent figure standing at $918000.0 for Q1 2026.
- In Q1 2026, Leases fell 38.18% year-over-year to $918000.0; the TTM figure through Mar 2026 stood at $918000.0 (down 38.18% YoY), while the FY2025 annual figure was $1.3 million, down 28.3% from the prior year.
- Leases came in at $918000.0 for Q1 2026 at Rezolute, down from $1.1 million in the prior quarter.
- In the past five years, Leases ranged from a high of $2.3 million in Q4 2022 to a low of $130000.0 in Q3 2022.
- A 5-year average of $1.4 million and a median of $1.6 million in 2024 frame the typical range for Leases.
- Across the five-year window, Leases plunged 62.92% in 2022 and surged 1386.92% in 2023, its largest moves.
- Rezolute's Leases stood at $2.3 million in 2022, then fell by 7.15% to $2.1 million in 2023, then retreated by 23.99% to $1.6 million in 2024, then plunged by 34.28% to $1.1 million in 2025, then declined by 13.72% to $918000.0 in 2026.
- According to Business Quant data, Leases over the past three periods registered $918000.0, $1.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 918,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 918,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 2.01 Mn |
| Dec 31, 2023 | 2.13 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 2.05 Mn |
| Mar 31, 2023 | 2.17 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 130,000.00 |
| Jun 30, 2022 | 152,000.00 |
| Mar 31, 2022 | 175,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 317,000.00 |
| Jun 30, 2021 | 396,000.00 |
| Mar 31, 2021 | 472,000.00 |
| Dec 31, 2020 | 547,000.00 |
| Sep 30, 2020 | 325,000.00 |
| Jun 30, 2020 | 383,000.00 |
| Mar 31, 2020 | 441,000.00 |
| Dec 31, 2019 | 497,000.00 |
| Sep 30, 2019 | 552,000.00 |